November 30, 2022 01:59 PM EST
R&D
Law

Pro­tect­ing its megablock­buster, Janssen chal­lenges Am­gen's Ste­lara biosim­i­lar ahead of planned 2023 launch

Zachary Brennan

Senior Editor

John­son & John­son unit Janssen on Wednes­day sued Am­gen over the com­pa­ny’s pro­posed biosim­i­lar to its megablock­buster Ste­lara (ustek­inum­ab), af­ter Am­gen said it was ready to launch next May or as soon as the FDA signs off on it.

If Am­gen car­ries through with that plan, Janssen told the Delaware dis­trict court that the Thou­sand Oaks, CA-based com­pa­ny will in­fringe on at least two Janssen patents.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Oph­thalmic biotech rais­es $16.5M; Pfiz­er’s AI col­lab­o­ra­tion bears fruit

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py fa­cil­i­ty as it elim­i­nates jobs and costs

A service from the Financial Times